Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus.

ABSTRACT: Type 2 diabetes mellitus (DM) is a major cardiovascular (CV) risk factor and, as such, is considered a coronary artery disease risk equivalent. Although glycemic control is associated with decreased CV events epidemiologically, many prospective clinical trials have failed to conclusively demonstrate that aggressive glycemic control improves the CV prognosis of patients with type 2 DM, especially those with long-standing DM. Many therapies for type 2 DM with widely divergent mechanisms of action are available. Some of these drugs, in addition to their glucose-lowering actions, have properties that may reduce or increase CV events. Agents that lower both insulin resistance and postprandial hyperglycemia while at the same time avoiding hypoglycemia may be beneficial for CV health. This articl

SUBMITTER: O'Keefe JH 

PROVIDER: S-EPMC3031437 | biostudies-literature | 2011 Feb

REPOSITORIES: biostudies-literature